The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS)
- 673 Downloads
Objective: To test whether cannabinoids reduce urge incontinence episodes without affecting voiding in patients with multiple sclerosis. This was part of the multicentre trial of the Cannabinoids in Multiple Sclerosis (CAMS) study. Subjects and methods: The CAMS study randomised 630 patients to receive oral administration of cannabis extract, Δ9-tetrahydrocannabinol (THC) or matched placebo. For this substudy subjects completed incontinence diaries. Results: All three groups showed a significant reduction, p<0.01, in adjusted episode rate (i.e. correcting for baseline imbalance) from baseline to the end of treatment: cannabis extract, 38%; THC, 33%; and placebo, 18%. Both active treatments showed significant effects over placebo (cannabis extract, p=0.005; THC, p=0.039). Conclusion: The findings are suggestive of a clinical effect of cannabis on incontinence episodes in patients with MS. This is in contrast to the negative finding of the CAMS study, where no difference was seen in the primary outcome of spasticity.
KeywordsCannabis Cannabinoid Multiple sclerosis Urge incontinence Neurogenic detrusor overactivity Controlled trial
This study was funded by a grant from the Multiple Sclerosis Society. The Medical Research Council sponsored the main CAMS study. Solvay Healthcare Ltd. and the Institute for Clinical Research, IKF, Berlin, provided medication. We thank all patients who took part in the study. We acknowledge the assistance of the CAMS study team, particularly Jane Vickery for trial coordination and help with drafting the paper, Wendy Ingram for assistance with figure construction, Hilary Sanders for further statistical support as well as Suzi Reilly, Judy Willcocks, Sue Varley, Mark Warner, Lara Teare, Felicity Coates and Rosemary Bishop (urodynamic nurse).
- 8.Madersbacher H, Wyndaele JJ, Igawa Y, Chancellor M, Chartier-Kastler E, Kovindha A (2002) Conservative management in neuropathic urinary incontinence. In: Abrams P et al (eds) Incontinence: 2nd international consultation on incontinence, Health Publication Ltd., Plymouth, pp 697–754Google Scholar
- 15.Brady CM, DasGupta R, Wiseman OJ, Dalton CM, Berkley KJ, Fowler CJ (2002) The effect of cannabis based medicinal extract on lower urinary tract dysfunction in advanced multiple sclerosis: preliminary results. J Neurol Neurosurg Psychiatry 72(1):139Google Scholar
- 20.Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standardisation of terminology of lower urinary tract function: report from the of the International Standardisation Sub-Committee Continence Society. Neurourol Urodyn 21(2):167–178PubMedCrossRefGoogle Scholar
- 21.Artibani W, Andersen JT, Gajewski JB, Ostergard DR, Raz S, Tubaro A (2002) Imaging and other investigations. in: Abrams P et al (eds) Incontinence: 2nd international consultation on incontinence, Health Publication Ltd., Plymouth, pp 697–754Google Scholar
- 22.Goldstein H (1995) Multilevel statistical models, 2nd edn. Arnold, LondonGoogle Scholar
- 25.Greenland JE, Brading A (1995) The in-vitro effect of delta-9 tetrahydrocannabinol on the detrusor smooth muscle of the pig. Proceedings of the International Continence Society, Sydney, pp 87–88Google Scholar
- 26.Ost D, Van der Aa F, De Ridder D (2001) Immunohistochemical study of the cannabinoid receptors CB1 and CB2 in the human bladder. Mult Scler 7(1):S24Google Scholar
- 28.Blyweert W, Van der Aa F, De Ridder D (2003) Cannabinoid therapy in detrusor overactivity: local versus systemic effect in a spinalised rat model. Neurourol Urodyn 22(5):379–380Google Scholar